Home Tags Acute myeloid leukemia

Tag: acute myeloid leukemia

Innate Pharma Confirms Securing Investment to Develop Novel ADC

The French biotechnology company Innate Pharma, which focuses on the discovery as well as the development and commercialization of novel therapeutic antibodies-based therapeutics to...

IMGN779 Demonstrates Favorable Safety Profile with repeat Dosing and no Dose-limiting...

The first-in-human data demonstrate the safety and tolerability of IMGN779, being developed by ImmunoGen, across seven dose levels, with no dose limiting toxicities (DLTs),...

Pfizer Resubmits Application for Gemtuzumab Ozogamicin to European and American Regulators

In late January 2017 Pfizer's Biologics License Application (BLA) for gemtuzumab ozogamicin (Mylotarg®; previously known as CMA-676) was accepted for filing by the U.S....

Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...

Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...

First Patient Dosed in Phase I Trial of ADCT-301 Trial

Earlier this month ADC Therapeutics, a Swiss-based oncology drug development company, dosed the first patient in a Phase I trial to evaluate ADCT-301, also...

Study Links Gemtuzumab Ozogamicin Response in Pediatric AML to Expression Level...

Expression CD33 is largely restricted to hematopoietic cells. Because CD33 is consistently expressed on acute myeloid leukemia or AML blasts, it makes a promising...

IMGN779 Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML...

CD33 is broadly expressed on leukemic blasts of patients with acute myeloid leukemia.  Although nearly 80% of patients show a high initial response rates to chemotherapy, many...

Developing a New BiTe against Acute Myeloid Leukemia

Astellas Pharma Inc. (Tokyo, Japan) and The University of Texas MD Anderson Cancer Center (Houston, Texas) have signed an option agreement to research and develop...

Novel CD33-targeting Antibody-drug Conjugate IMGN779 Is Highly Active In Vitro and...

Acute myeloid leukemia (AML), the most common type of acute leukemia in adults which is also known as acute nonlymphocytic leukemia, is a cancer...

SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia

To-date, the treatment of acute myeloid leukemia or  AML remains general unsatisfactory.  Both the medical and scientific communities are looking for urgently needed novel...